Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib
30 oct. 2023 09h15 HE
|
Aptose Biosciences, Inc.
Aptose Presents Latest Available Data on AML Drug Tuspetinib - 48% ORR with TUS/VEN in Heavily Pre-treated R/R AML Patients
Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023
26 oct. 2023 07h11 HE
|
Aptose Biosciences, Inc.
Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023
Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th
23 oct. 2023 07h30 HE
|
Aptose Biosciences, Inc.
Aptose to Hold Clinical Update Webcast and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th
Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference
16 oct. 2023 07h30 HE
|
Aptose Biosciences, Inc.
Aptose to present TUS/VEN AML data at ESH; to hold clinical update webcast on October 30th. TUS appears to re-sensitize Prior-VEN failure patients to VEN.
Aptose to Present at the Cantor Global Healthcare Conference
18 sept. 2023 07h45 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical
06 sept. 2023 07h45 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference
24 août 2023 07h30 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Reports Results for the Second Quarter 2023
10 août 2023 16h02 HE
|
Aptose Biosciences, Inc.
─ CRc Response Rate 50% with Tuspetinib/Venetoclax Doublet in Evaluable Patients ─ ─ CRc 44% in Patients Who Failed Prior Venetoclax ── CRc 43% in Patients with Wildtype FLT3 ── CRc 67%...
Aptose to Report Second Quarter 2023 Financial Results and Hold Conference Call on Thursday, August 10, 2023
27 juil. 2023 16h04 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, July 27, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted...
Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
26 juin 2023 16h05 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, June 26, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...